TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05878132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable device -'Smart Reminder'
Description: The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 30-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The participants in the control group received similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They were instructed to perform the exercises for the recommended therapy dose and received a weekly therapy consultation as well. To monitor the participant's exercise compliance, they were instructed to record their daily exercise progress in the exercise log.
Study: NCT05319015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Lenvatinib
Description: 20 mg PO daily for 12 weeks prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Pembrolizumab
Description: 200 mg IV every 3 weeks for 4 doses prior to surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection
Description: Resection of locally advanced RCC with IVC tumor thrombus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Pembrolizumab
Description: 200 mg IV every 3 weeks for up to 13 doses after surgery
Study: NCT05282394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: abdominal massage

Intervention type: OTHER
Group type: OTHER
Intervention: Reading
Description: guidance given to parents about reading with baby
Study: NCT05111119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making PrEP Smart
Description: The Making PrEP Smart intervention is a mobile-based application with the following components:~* Notification-based PrEP Reminders and Adherence Self-Monitoring~* HIV self-testing facilitation, interpretation of results, and testing support~* HIV partner testing facilitation, interpretation of results, and testing support~* Nearby HIV clinic contact information
Study: NCT06021522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Selective dopamine D1 and D5 receptor antagonist
Study: NCT05980455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra® Therapy System
Description: The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra® Therapy System
Description: The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Study: NCT05831631

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating leukocytes immunophenotype
Description: Blood samples will be tested with flow cytometry in order to characterize leukocyte subpopulations and to evaluate the circulating immunophenotype

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor sampling
Description: Immunohistochemical analysis will be performed on tumor samples in order to characterize immune T cells distribution within the tumor.
Study: NCT06568783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FAPI-74
Description: \[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
Study: NCT06074601

Intervention type: DIAGNOSTIC_TEST
Intervention: Mirvie Predictive Test for Adverse Pregnancy Outcomes
Description: This is a proprietary biomarker and clinical factor-based algorithm for predicting which pregnancies are at greatest risk of developing a variety of adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)
Study: NCT03923322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botanical Tincture
Description: Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
Study: NCT05473182

Intervention type: OTHER
Group type: OTHER
Intervention: IndieTrainer system
Description: The IndieTrainer system is comprised of the IndieGo device and video-game modules. The IndieGo device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. The video-game modules are integrated into the IndieGo device such that the video games can be played on a TV screen using the specific access method used to control the IndieGo (i.e., switch or joystick). The IndieTrainer system is designed to allow a child to practice power wheelchair skills as part of the video-game modules or as part of more traditional power wheelchair skills training activities wherein children are able to actively explore the environment and practice executing actual wheelchair skills.
Study: NCT05331027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
Study: NCT06169397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTMAB-16
Description: XTMAB-16 infusion
Study: NCT06139692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients receive perioperative sedation with dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients receive perioperative sedation with midazolam
Study: NCT06560021

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy strategy
Description: Number of random biopsies, in addition to targeted biopsies, taken during colonoscopies where at least one indication for the colonoscopy is surveillance for dysplasia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy strategy
Description: Number of random biopsies, in addition to targeted biopsies, taken during colonoscopies where at least one indication for the colonoscopy is surveillance for dysplasia
Study: NCT06458959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEM+
Description: The Young Children's Participation in Environment Measure (YC-PEM), an evidence-based and promising electronic patient-reported outcome (e-PRO) when combined with the Participation and Environment Measure Plus (PEM+) care planning application that yields a summary report and is paired with a program-specific decision-support tool, may support family engaged Early Intervention (EI) service plan development. Intervention group caregivers will complete the YC-PEM e-PRO and PEM+ intervention before their child's annual review of progress. The online summary report will be combined with a program-specific decision-support tool to guide EI service plan development.
Study: NCT05007015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Irrigation
Description: Each participant will receive a mailed package of TAI materials, given access to the LARS website, and have two scheduled virtual visits with a trained research nurse to learn how to use TAI once assigned to the intervention arm. These sessions will include one on one session with the nurse for review of the material, discussion of the device and any questions. TAI involves introducing an applicator into the anus for irrigation. An initial volume of 1000 mL will be suggested but can be increased to 1500 mL or reduced to 500 mL as per patient preference and tolerance. Applicators are single-use instruments that can be disposed of into standard waster receptacle after each treatment. The irrigation system is multiple-use and can be used for the duration recommend by the manufacturer manual. Daily irrigation can take anywhere between 20 and 90 minutes depending on individual patient experience.
Study: NCT05980455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enterra® Therapy System
Description: The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Study: NCT06558214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune GIO®
Description: .~. Optune GIO® TTFields treatment will begin 3-7 days prior to MLA for Arm1 and 3-10 days prior to MLA for Arm 2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune GIO®
Description: .~. Optune GIO® TTFields treatment will begin 3-7 days prior to MLA for Arm1 and 3-10 days prior to MLA for Arm 2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroBlate®
Description: Treatment with NeuroBlate will occur one time at the beginning of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroBlate®
Description: Treatment with NeuroBlate will occur one time at the beginning of the study.
Study: NCT06375564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-AB-3PRGD2 radioligand therapy
Description: Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
Study: NCT04722653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: 1 single dose administered subcutaneously (s.c. - under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0194-0499 )
Description: 1 single dose administered subcutaneously (s.c. - under the skin).
Study: NCT06082271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Class III medical Hydrolyzed Collagen Peptides PEP-52 (Peptys)
Description: Anti-inflammatory and regenerative effect, 5 mg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone
Description: DEPO-MEDROL 40 mg/ml + 1 cc di NAROPINA 0,75% 7,5 mg/ml
Study: NCT06278909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal Nerve Stimulation
Description: Active trigeminal nerve stimulation
Study: NCT04862286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) injection.
Study: NCT06200194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiyoSmart Spectacles
Description: No power in the central optic zone of DIMS lens for premyopic children with normal vision. Before entering elementary school, eligible preschoolers are asked to wear the DIMS spectacles after kindergarten hours and during weekends and holidays. After entering elementary school, full-time mode wearing of DIMS spectacles is required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Description: daily use of non-preservative 0.01% atropine eye drop for each eye over the study period.
Study: NCT05893797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: As prescribed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tempo Smart Button
Description: Attached to the Tempo Pen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Continuous glucose monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glooko Research Medical App (RMA)
Description: Installed on a study provided android phone.
Study: NCT06005103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with MoodHeadBand (T-PEMF treatment)
Description: The patients will receive treatment with T-PEMF using a headband containing 20 coils placed symmetrically around the head of the patient. The device delivers 55 Hz magnetic field. Duration of treatment is 30 minutes once a day for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive treatment with MoodHeadBand (Placebo)
Description: Patients will use an identical device, which does not deliver T-PEMF treatment. The patients will use the headband as the active group for 30 minutes, once a day, for 8 weeks.
Study: NCT05279794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jones Group (Strain Counterstrain)
Description: No pain positioning technique with diaphragmatic breathing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Induction Group
Description: Myofascial Induction technique on the lumbar fascia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: No pain positioning of participants
Study: NCT06111326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3402 injection
Description: Intravenous infusion, once every 2 weeks, 4 weeks/cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab injection
Description: Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
Study: NCT05496426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL130008/Placebo
Description: Drug: KL130008 Drug: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL130008/Placebo
Description: Drug: KL130008 Drug: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL130008/Placebo
Description: Drug: KL130008 Drug: Placebo
Study: NCT05303649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive transcranial brain stimulation: excitatory iTBS
Description: 600 pulses (3 pulses at 50 Hz given every 200 milliseconds in 2-second trains at 10-second intervals, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 Device: Magstim Co., Wales, UK.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive transcranial brain stimulation: inhibitory cTBS
Description: 600 pulses (3 pulses at 50 Hz, repeated at 5 Hz, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 homologue Device: Magstim Co., Wales, UK.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual speech-language therapy (SLT)
Description: 45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual speech-language therapy (SLT)
Description: 45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Individual speech-language therapy (SLT)
Description: 45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS simulating left hemispheric iTBS
Description: Sham TMS coil positioned exactly like an active TMS coil resulting in a very good approximation of the auditory effects Device: Magstim Co., Wales, UK.
Study: NCT03864094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: 0,1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 1 microg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: 0,1 microg/kg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium chloride
Description: 0,1 ml/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2 mg/kg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: 2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1,7 microg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1,7 microg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1,7 microg/kg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Remifentanil
Description: 1,7 microg/kg
Study: NCT04989517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT193
Description: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AT193
Description: Topical
Study: NCT05496426

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KL130008/Placebo
Description: Drug: KL130008 Drug: Placebo
Study: NCT06207175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nonavalent HPV study vaccine
Description: A 3-dose regimen administered at months 0, 2 and 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL® 9
Description: A 3-dose regimen administered at months 0, 2 and 6.
Study: NCT05269134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriophage
Description: Phage Therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06302205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The home-based training intervention consists of two phases of each three months in duration. It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The home-based training intervention consists of two phases of each three months in duration. It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: 2 times a week, flexibility and balance training
Study: NCT05181917

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STUDIA app
Description: STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STUDIA app
Description: STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
Study: NCT06094777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY-0102
Description: Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
Study: NCT00013039

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer reminders
Study: NCT04003506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: LIA with ACB will be given using 20ml 0.5% standard bupivacaine